Comparison of serum tumor associated material (TAM) with conventional biomarkers in cancer patients

Asian Pacific Journal of Cancer Prevention

Volumn 13, Issue 5, 2012, Pages 2399-2403

  Shu, Jian ^a,b   Li, Cheng Guang ^a,c   Liu, Yang Chen ^d   Yan, Xiao Chun ^e   Xu, Xu ^f   Huang, Xin En ^a   Cao, Jie ^a   Li, Ying ^a   Lu, Yan Yan ^a   Wu, Xue Yan ^a   Liu, Jin ^a   Xiang, Jin ^a  

^a JIANGSU CANCER HOSPITAL   (China)

^b Department of Oncology   (China)

^c NANTONG UNIVERSITY   (China)

^d Taixing People's Hospital   (China)

^e Department of Medical Oncology   (China)

^f Department of Medical Oncology   (China)

Author keywords

Cancer; TAM; Tumor asscociated material; Tumor marker

Indexed keywords

ALPHA FETOPROTEIN; CA 19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; GLYCOLIPID; GLYCOPROTEIN; MUCIN 1; TUMOR MARKER;

ARTICLE; BLOOD; CANCER STAGING; COMPARATIVE STUDY; FEMALE; HUMAN; MALE; METABOLISM; MIDDLE AGED; NEOPLASM; PROGNOSIS;

ALPHA-FETOPROTEINS; CA-19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; FEMALE; GLYCOLIPIDS; GLYCOPROTEINS; HUMANS; MALE; MIDDLE AGED; MUCIN-1; NEOPLASM STAGING; NEOPLASMS; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84872682298     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2012.13.5.2399     Document Type: Article

References (49)

1. Basu PS, Majhi R, Batabyal SK (2003). Lectin and serum-PSA interaction as a screeninng test for prostate cancer. Clin Biochem, 36, 373-6.
2. Bosl GJ, Motzer RJ (1977). Testicular germ-cell cancer. N Engl J Med, 337, 242-51.
3. Boucher D, Cournoyer D, Stanners CP, et al (1989). Studies on the control of gene expression of the carcinoembryonic antigen family in human tissue. Cancer Res, 49, 847-52.
4. Duffy MJ (2001). Carcinoembryonic antigen as a marker for colorectal cancer: is it clinically useful? Clin Chem, 47, 624-30.
5. Duffy MJ (2006). Serum tumor markers in breast cancer: are they of clinical value? Clin Chem, 52, 345-51.
6. Duffy MJ, Sturgeon C, Lamerz R, et al (2010). Tumor markers in pancreatic cancer: a European Group on Tumor Markers (EGTM) status report. Ann Oncol, 21, 441-7.
7. Fujiyama S, Tanaka M, Maeda S, et al (2002). Tumor markers in early diagnosis, follow-up and management of patients with hepatocellular carcinoma. Oncology, 62, 57-63.
8. Gabius HJ (1988). Tumor lectinology- at the intersection of carbohydrate chemistry, biochemistry, cell biology, and oncology. Angew Chem, 27, 1267-76.
9. Gao LL, Huang XE, Zhang Q, et al (2011). 14.A Cisplatin and vinorelbine (NP) regimen as a postoperative adjuvant chemotherapy for completely resected breast cancers in China: final results of a phase II clinical trial. Asian Pac J Cancer Prev, 12, 77-80.
10. Gold P, Freedman SO (1965). Demonstration of tumor-specific antigens in human colonic carcinomata by immunologica ltolerance and absorption techniques. J Exp Med, 121, 439-62.
11. Gold P, Freedman SO (1965). Specific carcinoembryonic antigens of the human digestive system. J Exp Med, 122, 467-81.
12. Goggins M (2005). Molecular markers of early pancreatic cancer. J Clin Oncol, 23, 4524-31.
13. Gong P, Huang XE, Chen CY, et al (2012). Comparison on complications of peripherally inserted central catheters by ultrasound guide or conventional method in cancer patients. Asian Pacific J Cancer Prev, (in press).
14. Hakomori S (2000). Traveling for the glycosphingolipid path. Glycoconj J, 17, 627-47.
15. Hakomori S, Zhang Y (1997). Glycosphingolipid antigens and cancer therapy. Chem Biol, 4, 97-104.
16. Hollingsworth MA, Swanson BJ (2004). Mucins in cancer: Protection and control of the cell surface. Nat Rev Cancer, 4, 45-60.
17. Huang XE, Li CG, Li Y, et al (2011). Weekly TP Regimen as a postoperative adjuvant chemotherapy for completely resected breast cancer in China: final result of a Phase II trial. Asian Pacific J Cancer Prev, 12, 2797-800.
18. Jiang M, Pu R (2010). Study on serum tumor related material (BXTM) with early diagnosis in malignant tumor. National Med Frontiers of China, 5, 80-1.
19. Jiang Y, Huang XE, Yan PW, et al (2010). Validation of treatment efficacy of a computer-assisted program for breast cancer patients receiving postoperative adjuvant chemotherapy. Asian Pacific J Cancer Prev, 11, 1059-62.
20. Khien VV, Mao HV, Chinh TT, et al (2001). Clinical evaluation of lentil lectin-reactive alpha-fetoprotein-L3 in histologyproven hepatocellular carcinoma. Int J Biol Markers, 16, 105-11.
21. Kui Wong N, Easton RL, Panico M, et al (2003). Characterization of the oligosaccharides associated with the human ovarian tumor marker CA125. J Biol Chem, 278, 28619-34.
22. Li CG, Huang XE, Li Y, et al (2011). Clinical observations on safety and efficacy of OxyContin® administered by rectal route in treating cancer related pain. Asian Pac J Cancer Prev, 12, 2477-8.
23. Li CG, Huang XE, Li Y, et al (2011). Phase II trial of irinotecan plus nedaplatin (INP) in treating patients with extensive stage small cell lung cancer. Asian Pacific J Cancer Prev, 12, 487-90.
24. Li CG, Huang XE, Xu L, et al (2012). Clinical application of serum Tumor Associated Material (TAM) from non-small cell lung cancer patients. Asian Pacific J Cancer Prev, 13, 301-4.
25. Liu ZM (1986). Serum free proline and free hydroxyproline and its peptide-binding determination of hydroxyproline in the evaluation of bone tumors. Chin J Lab Med, 9, 129-33.
26. Li Y, Yan PW, Huang XE, et al (2011). MDR1 Gene C3435T polymorphism is associated with clinical outcomes in gastric cancer patients treated with postoperative adjuvant chemotherapy. Asian Pacific J Cancer Prev, 12, 2405-9.
27. MacDonald JS (1999). Carcinoembryonic antigen screening: Pros and cons. Sem Oncol, 26, 556-60.
28. Meezan E, Wu HC, Black PH, et al (1969). Comparative studies on carbohydrate-containing membrane components of normal and virus-transformed mouse fibroblasts. Separation of glycoproteins and glycopeptides by sephadex chromatography. Biochemistry, 8, 2518-24.
29. Orntoft TF, Vestergaard EM (1999). Clinical aspects of altered glycosylation of glycoproteins in cancer. Electrophoresis, 20, 362-71.
30. Peracaula R, Tabarés G, Royle L, et al (2003). Altered glycosylation pattern allows the distinction between prostatespecifc antigen (PSA) from normal and tumor origins. Glycobiology, 13, 457-70.
31. Saussez S, Marchant H, Nagy N, et al (1998). Quantitative glycohistochemistry defines new prognostic markers for cancers of the oral cavity. Cancer, 82, 252-60.
32. Sell S (1990). Cancer-associated carbohydrates identified by monoclonal antibodies. Human Path, 21, 1003-19.
33. Serum tumor associated material (TAM) testing kit, QINGDAO BO-XING Biotechnology Co., Ltd. http://www.cqtrueway. com..
34. Steinberg W (1990). The clinical utility of the CA 19-9 tumorassociated antigen. Am J Gastroenterol, 85, 350-5.
35. Taylor-Papadimitriou J, Epenetos AA (1994). Exploiting altered glycosylation patterns in cancer- progress and challenges in diagnosis and therapy. Trends Biotech, 12, 227-33.
36. Turner GA(1992). N-Glycosylation of serum-proteins in disease and its investigation using lectins. Clin Chim Acta, 208, 149-71.
37. Wu W, Yao DF, Gu LH, et al (2006). Determination of hepatoma-specifc alpha-fetoprotein by a mini-column affnity chromatography method. Chin J Clin Lab Sci, 24, 10-2.
38. Xu HX, Huang XE, Li Y, et al (2011). A clinical study on safety and efficacy of Aidi injection combined with chemotherapy. Asian Pac J Cancer Prev, 12, 2233-6.
39. Xu HX, Huang XE, Qian ZY, et al (2011). Clinical observation of Endostar® combined with chemotherapy in advanced colorectal cancer patients. Asian Pac J Cancer Prev, 12, 3087-90.
40. Xu JW, Li CG, Huang XE, et al (2011). Ubenimex capsule improves general performance and chemotherapy related toxicity in advanced gastric cancer cases. Asian Pac J Cancer Prev, 12, 985-7.
41. Yan PW, Huang XE, Jiang Y, et al (2010). A clinical comparison on safety and efficacy of Paclitaxel/Epirubicin (NE) with Fluorouracil/Epirubicin/Cyclophosphamide (FEC) as postoperative adjuvant chemotherapy in breast cancer. Asian Pac J Cancer Prev, 11, 1115-8.
42. Yan PW, Huang XE, Yan F, et al (2011). Influence of MDR1 gene codon 3435 polymorphisms on outcome of platinum-based chemotherapy for advanced non small cell lung cancer. Asian Asian Pacific Journal of Cancer Prevention, Vol 13, 2012 2403 DOI:http://dx.doi.org Pac J Cancer Prev, 12, 2291-4.
43. Yao DF, Jiang DR, Huang ZW, et al (2000). Abnormal expressiom of hepatoma specifc ?-glutamyl transferase and alteration of ?-glutamyl transferase gene methylation status in patients with hepatocellular carcinoma. Cancer, 88, 761-9.
44. Yu DS, Huang XE, Zhou JN, et al (2012). A comparative study on the value of anal preserving surgery for aged people with low rectal carcinoma in Jiangsu, China. Asian Pacific J Cancer Prev, (in press).
45. Zhang LQ, Huang XE, Wang J (2011). The cyclin D1 G870A polymorphism and colorectal cancer susceptibility: a metaanalysis of 20 populations. Asian Pac J Cancer Prev, 12, 81-5.
46. Zhang S, Cordon-Cardo C, Zhang HS, et al (1997). Selection of tumor antigens as targets for immune attack using immunohistochemistry: I. Focus on gangliosides. Int J Cancer, 73, 42-9.
47. Zhang S, Zhang HS, Cordon-Cardo C, et al (1997). Selection of tumor antigens as targets for immune attack using immunohistochemistry: II. Blood group-related antigens. Int J Cancer,73, 50-6.
48. Zhang XZ, Huang XE, Xu YL, et al (2012). A Phase II study on voriconazole in treating chinese patients with malignant hematological disorder and invasive aspergillosis. Asian Pacific J Cancer Prev, (in press).
49. Zhou JN, Huang XE, Ye Z, et al (2009). Weekly paclitaxel/Docetaxel combined with a paltinum in the treatment of advanced non-samll cell lung cancer: a study on efficacy, safety and pre-medication. Asian Pac J Cancer Prev, 10, 1147-50.